Is CEL-SCI Corporation (CVM) a Buy, Sell, or Hold?
CEL-SCI Corporation
AMEX:CVM
$1.15 USD
-$0.07 (-5.74%)
- Volume
- 321.73K
- Average Volume
- 506.91K
- Market Capitalization
- $7.9M
- P/E Ratio
- -0.33
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $13.48
- Year Low
- $0.89
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.60
Industry, Sector & symbol
| Stock Exchange | AMEX |
| CEO | Geert R. Kersten |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CVM |
| CUSIP | 150837706 |
| CIK | 0000725363 |
| Web | https://cel-sci.com |
| Phone | 703 506 9460 |
| Currency | USD |
| Employees | 43 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.24 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.60 |
| Quick Ratio | 0.54 |
| Cash Ratio | 0.39 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.05 |
| Price / Cash Flow | -0.47 |
| Price / Book | 1.36 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.27 |
| Trailing P/E Ratio | -0.33 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-25.41M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -221.50% |
| Return on Assets | -128.20% |
Financials Score
| AltmanZ Score | -47.30 |
| Piotroski Score | 2.00 |
| Working Capital | -1.91M |
| Total Assets | 17.71M |
| Ebit | -22.19M |
| Market Cap | 8.59M |
| Total Liabilities | 10.83M |
Poll Results
About CEL-SCI Corporation (AMEX:CVM) Stock
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targetin ... g the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
2026-07-13 08:00:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.
2026-06-24 08:00:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #BIO2026--CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care.
CEL-SCI Announces Closing of Offering
2026-06-16 16:01:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of offering.
2026-06-16 08:00:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI advances Multikine immunotherapy for Head and Neck Cancer through dual U.S. registration study and Saudi market entry strategy.
CEL-SCI Corporation Announces Pricing of Offering
2026-06-14 19:03:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation announces pricing of offering.
2026-06-12 08:00:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI and Saudi Amarox to conduct signing ceremony at BIO 2026 for Strategic Agreement to advance commercialization and distribution of Multikine.
CEL-SCI Reports Fiscal Second Quarter 2026 Results
2026-05-18 08:00:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.
CEL-SCI Announces Closing of Public Offering
2026-05-13 15:00:00
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering.
Frequently Asked Questions
-
What is the current CEL-SCI Corporation (CVM) stock price?
-
CEL-SCI Corporation(AMEX:CVM) stock price is $1.15 in the last trading session. During the trading session, CVM stock reached the peak price of $13.48 while $0.89 was the lowest point it dropped to. The percentage change in CVM stock occurred in the recent session was --5.74% while the dollar amount for the price change in CVM stock was -$-0.07.
-
CVM's industry and sector of operation?
-
The AMEX listed CVM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CVM?
-
Geert R. Kersten | CEO, CAO,Treasurer and Director
Patricia Prichep | Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary
Eyal Talor | Chief Scientific Officer
John Cipriano | Senior Vice President of Regulatory Affairs
| -
How many employees does CVM have?
-
Number of CVM employees currently stands at 43. CVM operates from 8229 Boone Boulevard, Vienna, VA 22182, US.
-
Link for CVM official website?
-
Official Website of CVM is: https://cel-sci.com
-
How do I contact CVM?
-
CVM could be contacted at phone #703 506 9460 and can also be accessed through its website. CVM operates from 8229 Boone Boulevard, Vienna, VA 22182, US.
-
How many shares of CVM are traded daily?
-
The average number of CVM shares traded daily for last 3 months was 506.91K.
-
What is the market cap of CVM currently?
-
The market value of CVM currently stands at $7.9M with its latest stock price at $1.15